Skip to content

Price / earnings at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
23.4×-3.3×
Sotera Health logo
Sotera HealthSHC
34.6×-98.6×
Revvity logo
RevvityRVTY
40.9×-3.5×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
44.6×
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
29.6×+7.3×
IQVIA logo
IQVIAIQV
20.7×-2.6×

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Calculated from Charles River Laboratories’s reported figures.

Based on the most recent quarter.

The official record: Charles River Laboratories’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's price / earnings?
Charles River Laboratories (CRL) reported price / earnings of 24× in Q3 2024.
How has Charles River Laboratories's price / earnings changed year-over-year?
Charles River Laboratories's price / earnings increased by 13.4% year-over-year, from 21.2× to 24×.
What is the long-term trend for Charles River Laboratories's price / earnings?
Over 3 years (2020 to 2023), Charles River Laboratories's price / earnings has grown at a -9.6% compound annual growth rate (CAGR), from 34.6× to 25.5×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.